Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

E. Sands, Bruce; Jacobson, Eric; Sylwestrowicz, Thomas; Younes, Ziad; W. Dryden, Gerald; N. Fedorak, Richard; Greenbloom, Susan

doi:10.1002/ibd.21159

Public

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

Published in Inflammatory Bowel Diseases • Nov 16, 2009

Authors:

Bruce E. Sands

Eric Jacobson

Thomas Sylwestrowicz

Abstract

BACKGROUND: Interleukin-12 (IL-12) and interleukin-23 (IL-23) are inflammatory cytokines linked to the Th-1 and Th-17 phenotypes associated with Crohn's disease (CD). We investigated the activity and safety of apilimod mesylate (formerly STA-5326), an oral IL-12 and IL-23 inhibitor, in patients with...

Subject

Crohn's disease

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!